Celldex Therapeutics, Inc. (CLDX) Stock Price & Analysis
Celldex Therapeutics, Inc. (CLDX) rose 0.79% to USD 39.68 as of September 8, 2026 at 05:45 UTC, according to Nexqual real-time market data.
CLDX last closed at USD 39.68; the session ranged USD 38.9–39.81 on volume of 414,532 shares. Market capitalization is —, with a 52-week range of USD 22.1–45.14 (NCM). Source: Nexqual, September 8, 2026 at 05:45 UTC.
Key Statistics (as of September 8, 2026 at 05:45 UTC)
| Price | USD 39.68 |
|---|---|
| Change | ▲ 0.79% (up) |
| Previous Close | USD 39.68 |
| Open | USD 39.68 |
| Day Range | USD 38.9 – 39.81 |
| 52-Week Range | USD 22.1 – 45.14 |
| Volume | 414,532 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CLDX)
Nexqual's technical model rates CLDX "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:45 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.68 (neutral) |
| vs SMA50 | Above (USD 39.01) |
| MACD | 0.13 (positive) |
From Celldex Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- This approach allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | USD 28.02 | ▼ 3.15% |
| EXEL | Exelixis, Inc. | USD 59.01 | ▲ 0.82% |
| AGEN | Agenus Inc. | USD 8.24 | ▲ 1.85% |
| HALO | Halozyme Therapeutics, Inc. | USD 110.19 | ▲ 0.48% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 33.1 | ▼ 3.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:45 UTC. This page is informational and not investment advice.